XML 56 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Concentration of Business Risk (Tables)
 12 Months Ended
Dec. 31, 2012
Concentration of Business Risk [Abstract]  
Revenue by geographic area
                         
    Year Ended December 31,  
    2012     2011     2010  

North America

   $ 18,395     $ 18,971     $ 11,275  

Europe

     30,418       29,851       32,376  

South America

     7,224       11,300       7,287  

Asia

     1,134       1,145       1,135  
   

 

 

    

 

 

    

 

 

  
    $ 57,171     $ 61,267     $ 52,073  
   

 

 

    

 

 

    

 

 

  
Product and manufacturing revenues by individual product line
                                                 
    Years Ended December 31,  
    2012     % of
Total		     2011     % of
Total		     2010     % of
Total		  

Product revenues:

                                                

Animal health and nutrition

   $ 30,849       64 %    $ 33,850       60 %    $ 32,588       65 % 

Grain processing

     10,865       22 %      15,953       28 %      13,439       27 % 

Oilseed processing (1)

     579       1 %      5,352       10 %      3,322       6 % 

All other products

     1,062       2 %      840       2 %      1,002       2 % 
   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total product revenue

   $ 43,355       89 %    $ 55,995       100 %    $ 50,351       100 % 

Contract manufacturing (1)

     5,547       11 %      0       0 %      0       0 % 
   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total product and contract manufacturing revenue

   $ 48,902       100 %    $ 55,995       100 %    $ 50,351       100 % 
   

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

 

(1) The Company continues to provide manufacturing services for the products sold and licensed to DSM. All revenue after the agreement date (March 23, 2012) is classified as contract manufacturing revenue within the Company’s product line item on the consolidated statements of comprehensive income. All historical amounts related to Purifine and Veretase will continue to be shown as oilseed processing and grain processing product revenue, respectively.